EACS 2023: TDF/FTC dual-nuke ART: not supported by ALTAR study
1 December 2023. Related: Conference reports, Treatment strategies.
Treatment strategies
Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants
1 December 2023. Related: Treatment strategies.
CD4:CD8 ratio recovery reduces with higher age when starting ART
1 December 2023. Related: Treatment strategies, Basic science and immunology.
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study
1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance.
IAS 2023: Rapporteur summary Track D – social and behavioural science
1 September 2023. Related: Conference reports, Treatment strategies.
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
UK cascade data cautions UNAIDS 95:95:95 targets: re-engaging people in care
1 June 2023. Related: Conference reports, Treatment strategies, Treatment advocacy.
Selected webcasts from BHIVA 2023
1 June 2023. Related: Conference reports, Treatment strategies, Side effects, Lipodystrophy and metabolic complications.
ART increases life expectancy by 30 to 40 years: impact of CD4 count, sex and calendar year
1 June 2023. Related: Antiretrovirals, Treatment strategies, Ageing and life expectancy.
CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
10 March 2023. Related: Conference reports, Treatment strategies, Drug resistance.
More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART
1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Drug resistance.
Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens
1 December 2022. Related: Conference reports, Treatment strategies.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results
1 July 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Updates from the VESTED study
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
EACS 2021: a call for collaborations and for both HIV and COVID-19
31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
12 March 2021. Related: Conference reports, Treatment strategies.
Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study
22 January 2021. Related: Treatment strategies, Drug resistance.
Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain
28 August 2020. Related: Conference reports, Treatment strategies.
Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study
28 August 2020. Related: Conference reports, Treatment strategies.
Early drugs being studied for COVID-19
27 March 2020. Related: Treatment strategies, COVID-19: investigational drugs, COVID-19.
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
23 August 2019. Related: Conference reports, Treatment strategies.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
bNAb research at CROI 2019: vaccine, prevention, treatment and cure…
30 April 2019. Related: Conference reports, Treatment strategies, HIV prevention and transmission, Cure-related research.
Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Same-day ART is effective in San Francisco Rapid-ART clinic
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Viral reservoir can explain persistent low level viraemia with good adherence on ART
12 March 2019. Related: Conference reports, Treatment strategies.
Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual bNAb maintains viral suppression for median 21 weeks off-ART
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dolutegravir monotherapy: still no longer recommended in either research or clinical practice
24 August 2018. Related: Conference reports, Treatment strategies.
Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study
3 August 2018. Related: Conference reports, Treatment strategies.
M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy
16 April 2018. Related: Conference reports, Treatment strategies, Drug resistance.
Early ART is not associated with a higher risk of HIV drug resistance
5 January 2018. Related: Treatment strategies, Drug resistance.
Dolutegravir-based dual therapy as switch option in multiple studies
28 November 2017. Related: Conference reports, Treatment strategies.
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART
24 April 2017. Related: Conference reports, Treatment strategies, Basic science and immunology.
Increased risk of IRIS with integrase inhibitors reported in two studies
24 April 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Coinfections and complications.
Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue
27 February 2017. Related: Conference reports, Treatment strategies.
Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not
29 November 2016. Related: Conference reports, Treatment strategies.
Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep
1 October 2016. Related: Conference reports, Treatment strategies.
Four day a week ART: sub-optimal drug levels but few virological failures
1 October 2016. Related: Conference reports, Treatment strategies.
ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms
1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study
1 August 2016. Related: Conference reports, Treatment strategies.
Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio
1 August 2016. Related: Conference reports, Treatment strategies.
Further results using dolutegravir monotherapy: urgent need for controlled studies
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Potential economic impact of dolutegravir/3TC dual therapy
1 February 2016. Related: Antiretrovirals, Treatment strategies.
First-line ART with dolutegravir plus 3TC: 24-week early results
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Four reasons IAS 2015 will be a milestone HIV conference: a personal view
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.
Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
The option for same day antiretroviral therapy on diagnosis: the future model for HIV care
1 August 2015. Related: Conference reports, Treatment strategies, Treatment access, Treatment advocacy, Other news.
Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA
1 August 2015. Related: Conference reports, Treatment strategies.
HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance
1 August 2015. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500
24 March 2015. Related: Conference reports, Treatment strategies, TB coinfection.
Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study
24 March 2015. Related: Conference reports, Treatment strategies, Paediatric care.
Gender differences in use of cardiovascular disease-related interventions: D:A:D study
1 December 2014. Related: Conference reports, Treatment strategies, Women's health, Side effects.
Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis
1 August 2014. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
No difference in overall anaemia rate with reduced dose AZT
1 August 2014. Related: Conference reports, Treatment strategies, Treatment access.
Fit for purpose: treatment optimisation 2014
19 July 2014. Related: Pipeline report, Fit for purpose, Treatment strategies.